Lilly to buy immuno-oncology firm Armo BioSciences for $1.6bn

This article was originally published here

Eli Lilly and Company (Lilly) has agreed to acquire Armo BioSciences, a US-based late-stage immuno-oncology company, for about $1.6bn in an all-cash deal.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply